Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography

Dinesh Khanna1, Oliver Distler2, Vincent Cottin3, Kevin K Brown4, Lorinda Chung5, Jonathan G Goldin6, Eric L Matteson7, Ella A Kazerooni8,9, Simon LF Walsh10, Michael McNitt-Gray11,12 and Toby M Maher13,14

Abstract
Patients with systemic sclerosis are at high risk of developing systemic sclerosis–associated interstitial lung disease. Symptoms and outcomes of systemic sclerosis–associated interstitial lung disease range from subclinical lung involvement to respiratory failure and death. Early and accurate diagnosis of systemic sclerosis–associated interstitial lung disease is therefore important to enable appropriate intervention. The most sensitive and specific way to diagnose systemic sclerosis–associated interstitial lung disease is by high-resolution computed tomography, and experts recommend that high-resolution computed tomography should be performed in all patients with systemic sclerosis at the time of initial diagnosis. In addition to being an important screening and diagnostic tool, high-resolution computed tomography can be used to evaluate disease extent in systemic sclerosis–associated interstitial lung disease and may be helpful in assessing prognosis in some patients. Currently, there is no consensus with regards to frequency and scanning intervals in patients at risk of interstitial lung disease development and/or progression. However, expert guidance does suggest that frequency of screening using high-resolution computed tomography should be guided by risk of developing interstitial lung disease. Most experienced clinicians would not repeat high-resolution computed tomography more than once a year or every other year for the first few years unless symptoms arose. Several computed tomography techniques have been developed in recent years that are suitable for regular monitoring, including low-radiation protocols, which, together with other technologies, such as lung ultrasound and magnetic resonance imaging, may further assist in the evaluation and monitoring of patients with systemic sclerosis–associated interstitial lung disease. A video abstract to accompany this article is available at: https://www.globalmedcomms.com/respiratory/Khanna/HRCTinSScILD

Keywords
Systemic sclerosis, interstitial lung disease, progressive fibrosing, high-resolution computed tomography, radiation, imaging

Date received: 28 April 2021; accepted: 12 May 2021

1Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
3Hospices Civils de Lyon, Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, INRAE, UMR754, University Claude Bernard Lyon 1, Lyon, France
4Department of Medicine, National Jewish Health, Denver, CO, USA
5Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA
6David Geffen School of Medicine and UCLA Medical Center, Los Angeles, CA, USA
7Division of Pulmonary Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
8National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
9Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
10Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
11National Heart and Lung Institute, Imperial College London, London, UK
12Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

Corresponding author:
Dinesh Khanna, University of Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI 48109, USA.
Email: khannad@med.umich.edu
Introduction

Among patients with systemic sclerosis (SSc), there is a high risk of developing interstitial lung disease (ILD), which when present is associated with respiratory impairment, reduced quality of life and increased risk of death. Early and accurate diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) facilitates clinical management, and the most sensitive and specific diagnostic modality is high-resolution computed tomography (HRCT) of the chest. The utility of HRCT in SSc-ILD is not limited to screening and diagnosis, as it is also useful in disease monitoring and determining prognosis. However, HRCT may be underused in patients with SSc-ILD.

This review will highlight the importance of early diagnosis in SSc-ILD, focusing on the use of HRCT of the chest as a screening, diagnostic, prognostic, and monitoring tool, as well as the evolution of chest imaging techniques.

SSc-ILD

SSc is a heterogeneous autoimmune connective tissue disease characterized by skin thickening and progressive fibrosis of the skin and internal organs. Patients with SSc are at high risk of developing ILD, which causes significant morbidity and mortality: symptoms and outcomes range from subclinical lung involvement to major pulmonary disease, respiratory failure, and death. Pulmonary fibrosis resulting from ILD is one of the leading causes of mortality in patients with SSc, responsible for up to 17% of SSc-related deaths.

Many patients with SSc-ILD experience clinically significant progression, and clinical outcome is worse in patients with more extensive disease. While some patients may remain stable indefinitely, others decline and then become stable, whereas others will progress inexorably with a variety of trajectories. For example, in the European Scleroderma Trials and Research Group database, almost one-third of patients had stable lung function during 5 years of follow-up; however, among those with initial progression at 1 year, almost half showed further progression over 5 years.

Potential risk factors for any ILD in patients with SSc and for progression of ILD in SSc-ILD are shown in Table 1. However, it should be noted that some of these risk factors are yet to be confirmed or come from single-center cohorts. Risk factors for progression may also depend on the phase of the disease.

As the risk of developing ILD is greatest in the first few years after SSc diagnosis, screening patients with SSc for ILD may help with prognosis and management. Patients with clinically significant disease at baseline and those at high risk for clinically significant progression should be identified as early as possible. As the disease course is variable and difficult to predict, it is appropriate to monitor patients with SSc-ILD regularly for signs of progression.

Emphysema is independently associated with SSc, and like SSc-ILD, is best seen on HRCT. Combined pulmonary fibrosis and emphysema (CPFE) is also present in approximately 7%–18% of patients with SSc-ILD. Patients with CPFE-SSc have worse survival than with SSc-ILD and SSc-emphysema, and early diagnosis by HRCT is important for disease management.

For this review, the PubMed database was searched for all publications up to 1 July 2019 (date of the search) using the following search terms: (high-resolution computed tomography and systemic sclerosis) and (diagnosis or treatment); high-resolution computed tomography and (safety or interstitial lung disease). Publications relating to idiopathic pulmonary fibrosis or ILD not including SSc were excluded. Publications were additionally included based on the expert knowledge of the authors.

HRCT in SSc-ILD

Screening and diagnosis

Early detection of ILD in patients with SSc is important for baseline evaluation and for consideration of treatment interventions. Expert consensus recommendations endorse screening all patients using HRCT and lung function testing (Table 2).

HRCT of the chest is the most sensitive means of detecting SSc-ILD and is regarded as the gold standard for diagnosis. On initial HRCT, ILD is present in more than 50% of patients, including in some patients without symptoms. Signs of interstitial lung abnormalities and ILD (including ground-glass opacity, septal lines, and honeycombing in the patterns of non-specific interstitial pneumonia and usual interstitial pneumonia (UIP)) can be seen even when pulmonary function test (PFT) results are in the normal range. While PFTs alone may be insufficient for early diagnosis, PFTs should be performed at the time of SSc diagnosis and at regular follow-up intervals.

Despite expert recommendations, HRCT is currently underused in the screening and diagnosis of SSc-ILD. In a recent study, only 51% of general rheumatologists and 66% of SSc experts reported routinely ordering HRCT in all newly diagnosed patients with SSc. In addition to clinician specialty, factors affecting HRCT use may include clinician experience, lack of knowledge of guidelines, lack of routine progression of ILD, concerns about radiation exposure, as well as imaging cost and accessibility.

More research is needed before recommendations can be made about the benefits of routine follow-up HRCT imaging in asymptomatic patients who have a normal HRCT at baseline. Expert consensus suggests that frequency of screening using HRCT should be guided by risk...
of developing ILD (such as autoantibodies, cutaneous involvement, race, etc.), in combination with clinical symptoms and lung function. However, there is currently no consensus regarding HRCT screening intervals. Most experienced clinicians would not repeat HRCT more than once a year or every other year for the first few years unless symptoms arose. Likewise, the specifics of HRCT image acquisition (volumetric, inspiratory/expiratory images, and prone images) vary by institution. In all cases, the patient’s radiation exposure should be weighed against the anticipated benefits of the exam.

**Prognosis and monitoring**

HRCT may be helpful in assessing prognosis in some patients. HRCT data have been included in staging models to gauge ILD progression risk and predict prognosis. Further study is needed in this area, particularly with regards to whether HRCT findings can be used to predict response to treatment.

The extent of ILD involvement on HRCT has been shown to correlate with degree of functional impairment (New York Heart Association class) and lung function in patients with SSc-ILD. More extensive ILD on HRCT has been associated with a lower forced vital capacity (FVC) at initial assessment, a greater decline in FVC during follow-up, and early mortality. In a retrospective study of HRCTs from patients in the Australian Scleroderma Cohort Study, extensive disease involving more than 20% of the lung parenchyma on HRCT at baseline was associated with a three-fold increased risk of deterioration or death compared with limited disease, although this study

### Table 1. Potential risk factors for ILD and progression of ILD in SSc.

| Risk factor                                      | Reference                        |
|-------------------------------------------------|----------------------------------|
| Risk factors for ILD in SSc                     |                                  |
| Male gender                                     | Khanna et al.,1                  |
| Diffuse cutaneous SSc                           | Sanchez-Cano et al.,12 Nihtyanova et al.,17 |
| Anti-topoisomerase I antibodies                  | Nihtyanova et al.,17 Liaskos et al.,18 |
| African–American race                           | Steen et al.,19                  |
| Gastroesophageal reflux disease                 | Zhang et al.,20                  |
| Shorter disease duration                        | Winstone et al.,21 Moore et al.,22 Hoffmann-Vold et al.,23 |
| Extent of fibrosis on HRCT of >20%              | Khanna et al.,1 Hoffmann-Vold et al.,23 Goh et al.,24 |
| Decreased FVC at baseline                       | Khanna et al.,1 Nihtyanova et al.,17 |
| Decreased DL_{CO} at baseline                   | Khanna et al.,1 Nihtyanova et al.,17 |
| Decreased oxygen saturation                     | Wangkaew et al.,25 Wu et al.,26   |
| Presence of anti-topoisomerase I antibodies      | Nihtyanova et al.,17             |

ILD: interstitial lung disease; SSc: systemic sclerosis; HRCT: high-resolution computed tomography; FVC: forced vital capacity; DL_{CO}: diffusing capacity of the lungs for carbon monoxide.

### Table 2. Expert consensus regarding use of HRCT and PFTs in patients with SSc-ILD.

| Clinical scenario                        | Assessment(s)         | Expert consensus | Reference(s)                                      |
|-----------------------------------------|-----------------------|------------------|--------------------------------------------------|
| At the time of SSc diagnosis (may be asymptomatic) | Baseline HRCT screening | ++       | Denton et al.,2 Kowal-Bielecka et al.,2 Hoffmann-Vold et al.,4 Hoffmann-Vold et al.28 |
|                                        | Baseline PFTs         | ++       | Hoffmann-Vold et al.,4                           |
| Patients at high risk of ILD development (assuming negative baseline HRCT) | Repeated HRCT screening | +/-     | Hoffmann-Vold et al.,4                           |
|                                        | Repeated PFTs         | ++       | Hoffmann-Vold et al.,4                           |
| Patients at risk of ILD progression     | Repeated HRCT for monitoring | +/-     | Hoffmann-Vold et al.,4                           |
|                                        | Repeated PFTs         | ++       | Hoffmann-Vold et al.,4                           |
| Patients with a significant decline in PFT and/or worsening symptoms | HRCT                  | ++       | Hoffmann-Vold et al.,4                           |
|                                        | PFTs                  | ++       | Hoffmann-Vold et al.,4                           |

HRCT: high-resolution computed tomography; PFT: pulmonary function test; SSc: systemic sclerosis; ILD: interstitial lung disease. Consensus or evidence regarding how often to repeat screenings after initial screening is lacking.

Long-term stability is present in at least one-third of SSc-ILD patients. Other patients may show different patterns of ILD progression: periods of decline followed (or preceded) by periods of stability, multiple declines, or continuous progression.

Strong evidence: ++; mixed evidence: +/-.
did not account for time from first non-Raynaud symptom and could suffer from lead-time bias. The presence of fibrosis at baseline on HRCT was associated with mortality in multivariable modeling in patients with SSc-ILD in Norway. Although HRCT parameters were not shown to be predictive of survival in patients in one study of early SSc, a number of other published studies support the use of HRCT in determining the prognosis of patients with SSc-ILD.

Changes in extent or pattern on HRCT might be used to monitor disease progression in treated or untreated patients. Due to the heterogeneous longitudinal behavior, the risks of radiation exposure and imaging costs, there is currently no consensus on how often HRCT needs to be repeated (Table 2). The use of HRCT for monitoring disease progression is therefore guided by the clinician and is generally performed in response to worsening of symptoms, as this can be multifactorial in SSc (ILD, pulmonary hypertension, pulmonary embolism, emphysema, deconditioning, anemia, cardiac involvement, etc.). Clinicians may also order a follow-up HRCT scan when there are conflicting data between symptoms and PFTs, or suspicion of pulmonary embolism.

In summary, quantifying the degree of ILD on HRCT is potentially useful to evaluate prognosis and disease progression in SSc-ILD.

### Performing HRCT

#### History

HRCT was first introduced in the 1980s, when it transformed the diagnosis of diffuse lung disease, particularly fibrosing lung diseases, by providing detailed cross-sectional images of the lungs. Since that time, there have been tremendous developments in computed tomography (CT) technology that are relevant to the diagnosis and monitoring of SSc-ILD. Modern scanners use multidetector helical CT techniques to undertake volumetric scans of the entire thorax that can be reconstructed into thin (less than 1.25 mm) slices, enabling detection of the pattern and extent of subtle abnormalities. Scanner speed enables volumetric whole lung imaging at different states, each in a single breath-hold, such as inspiration and expiration. In addition, radiation dose-reduction techniques, such as automatic exposure control methods and tube current modulation, allow the radiation dose to be adapted to the size of the patient, and more efficient detector systems allow for lower radiation dose exposures to be performed while preserving image quality. Recently, advanced image reconstruction techniques, such as iterative reconstruction, allow even lower radiation dose techniques to be used while still preserving image quality. Thus, the clinician can now choose to use reduced-dose CT protocols for follow-up scans. These approaches are discussed in more detail below.

### Practical recommendations

Detailed practical recommendations for performing HRCT scans and interpreting the results for patients with predicted SSc-ILD have recently been described. Volumetric acquisition with thin slices using a supine inspiratory scan acquisition is recommended to allow reconstruction in the coronal and sagittal planes with sufficient image fidelity; reconstructions should be performed with less than 1.25-mm thick slices. Supine expiratory scans allow better detection of air trapping; if dependent density is observed, then a prone inspiratory scan should be conducted to allow differential diagnosis of early ILD from atelectasis. Moderate edge-enhancing reconstruction algorithms should be employed, as areas of pseudo-honeycombing may result from an algorithm that is too sharp. Specific breathing instructions should be provided to patients to ensure repeatability between scans. Scans should be reviewed immediately following acquisition. Whole-lung contiguous acquisition allows the application of advanced processing techniques, including whole-lung segmentation, volume measurements, and quantification of normal and abnormal lung tissue.

Minimum (MinIP) and maximum intensity projection (MaxIP) are post-processing techniques that convert the voxel with the lowest or highest density, respectively, on every view throughout the volume into a two-dimensional image. MinIP allows for improved detection of air trapping, can obviate the need for an expiratory scan, and is useful in the identification and quantification of ground-glass opacities. MaxIP can help improve the detection of nodules and micronodules associated with comorbidities.

### Minimizing radiation exposure in HRCT and the associated trade-offs

CT scans use ionizing radiation, which does carry some risks. These risks are stochastic in nature at the levels of radiation exposure associated with CT scans for SSc-ILD, and are primarily related to radiation-induced carcinogenesis. These are considered to be small, though non-zero, risks. The risks of ionizing radiation are higher in women and decrease with age. Therefore, balancing the radiation exposure to the patient, while maintaining sufficient image quality to obtain the desired diagnostic information, should always be considered. As mentioned above, there have been tremendous advances in CT scanner hardware and software that have allowed the generation of high-quality images of the entire lungs in a single breath-hold while requiring lower levels of radiation exposure. Measures to reduce HRCT-associated radiation exposure include the use of more efficient detector systems, automatic exposure control (such as tube current modulation), and advanced image reconstruction methods, such as iterative reconstruction techniques. In addition, further radiation dose...
reductions can be achieved by using limited axial scans (rather than helical scans), in which thin slices are acquired with large intervals (such as a 1-mm width acquisition spaced every 10 or 20 mm). While this reduces the radiation dose to the patient, it also substantially limits the amount of anatomy that is available for determining presence or severity of SSc-ILD.

Figure 1 shows HRCT images of a patient with SSc-ILD reconstructed with simulated dose reduction, keeping all other acquisition parameters the same. Some increased noise with loss of discrimination between the different manifestations of SSc-ILD can be seen. Iterative reconstruction techniques can allow the use of reduced radiation dose without compromising diagnostic accuracy (despite a possible loss of spatial resolution and differences in noise texture).\textsuperscript{53–55} A study of HRCT images from 55 patients with SSc-ILD found little difference between images generated using scans performed with a conventional (filtered back projection) reconstruction algorithm at 120 kV and 110 effective mAs (corresponding to a volume CT dose index (CTDI\textsubscript{vol}) of approximately 7.2 mGy) and those generated using 40% of that scanner output (120 kV, 44 effective mAs, corresponding to a CTDI\textsubscript{vol} of approximately 2.9 mGy), using an iterative reconstruction algorithm. Patients received either an estimated mean effective dose of 3.67 (range: 2.01–5.83) mSv when the full dose was used, or 1.8 (1.01–4.35) mSv with the dose reduction.\textsuperscript{54} However, an increase in image noise may be problematic for detecting subtle changes in SSc-ILD, for scanning larger patients at lower doses, and for applying computer-aided diagnosis and machine-learning techniques to CT data sets. Therefore, although promising, these findings should be replicated in other institutions using scanners from other manufacturers.

Several other studies have shown even greater dose reductions when applying iterative reconstruction methods without substantial loss of image quality, although their assessments of image quality were not always specific to

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{HRCT_images.png}
\caption{HRCT images comparing conventional versus reduced dose protocol in a patient with diffuse SSc-ILD. Axial thin section CT slice through the lower lobes of the lungs in a 35-year-old female patient with SSc with images reconstructed at simulated 10\%, 25\%, and 50\% of acquired dose (100\%). At all doses, the classic features of SSc-ILD can be identified; an NSIP pattern with peribronchovascular ground-glass and reticular opacities plus architectural distortion consistent with fibrosis. With decreasing dose, there is increased image noise resulting in loss of clarity of the different abnormalities due to loss of clarity of the ground-glass opacities as distinct from the reticular abnormalities.}
\end{figure}
SSc-ILD and included subjective assessments. Some simple quantitative assessments have been performed, and measures that primarily involve assessment of Hounsfield units (HU; for example, mean HU or mean HU in a region) are usually well preserved at very low doses.\textsuperscript{55} More complicated measures used in quantitative assessments (such as texture and others described below) have not been shown to be robust at these levels of dose reduction, and this is an area of further investigation.

CT scan protocols that do not use volumetric acquisition, but rather use a limited set of axial scans with large intervals between scans (for example, 1 mm scans every 10 or 20 mm), have also been used successfully to detect ILD in patients with SSc.\textsuperscript{56–58} This approach offers further radiation dose reduction, as a limited sample of lung anatomy is scanned instead of the entire lung, although these non-volumetric techniques may have limited assessment of regional variations or heterogeneity. By maintaining HRCT accuracy and sensitivity, these protocols enable detection of mild SSc-ILD while substantially reducing the estimated effective radiation dose.

Through automatic exposure control techniques and other technology developments, modern scanners use lower doses of radiation to achieve high-quality scans. The estimated effective dose of a standard HRCT scan is 2–4 mSv (Table 3).\textsuperscript{56} This is slightly higher than the estimated effective dose of a low-dose lung cancer screening CT exam (1–2 mSv)\textsuperscript{59,60} or chest X-ray (0.02–0.1 mSv)\textsuperscript{61} but is lower than the estimated effective dose of a routine diagnostic thoracic CT exam (estimated 5–7 mSv). The estimated effective dose from a standard HRCT scan is thus similar to the estimated naturally occurring background annual radiation in the United States (3.1 mSv)\textsuperscript{62} and the annual exposure for airline crew operating on long-haul flights (2–3 mSv).\textsuperscript{63} The estimated effective doses from HRCT scans can also be compared to the annual allowed exposure for radiation workers (including radiologists, radiologic technologists, and medical

### Table 3. Effective radiation dose for environmental exposure and different chest imaging protocols\textsuperscript{a}.

| Effective dose (mSv) | Equivalent background radiation (mSv) | Reference(s) Publication date |
|----------------------|--------------------------------------|-----------------------------|
| Annual exposure from background radiation in the United States | 3.1 | Ref Wakeford\textsuperscript{66} 2008 |
| Annual exposure of airline crews on long-haul flights | 2–3 | 0.66–1.0 Bagshaw\textsuperscript{63} 2008 |
| Annual allowable exposure limit for radiation workers (including radiologists, radiologic technologists, and medical physicists) | 50 | United States Nuclear Regulatory Commission,\textsuperscript{64} International Commission on Radiological Protection\textsuperscript{65} 2008 |
| Chest radiograph | 0.02–0.1 | Mettler et al.\textsuperscript{61} 2008 |
| Low-dose lung cancer screening CT | 1–2 | Larke et al.\textsuperscript{59} American Association of Physicists in Medicine\textsuperscript{60} 2011 & 2019 |
| Routine diagnostic chest CT | 5–7 | Larke et al.\textsuperscript{59} 2011 |
| Chest HRCT\textsuperscript{b} Standard protocol (reference value) | 1.6–4.0 | 0.54–1.30 Katsura et al.\textsuperscript{53} 2012 |
| | 1.8 | 0.58 Pontana et al.\textsuperscript{54} 2016 |
| | 0.85 | 0.28 Frauenfelder et al.\textsuperscript{56} 2014 |
| | 0.08 | 0.02 Winklehner et al.\textsuperscript{58} 2012 |
| 10-mm increment, 7-slice, and 3-slice protocols | 0.014–0.154 | 0.004–0.049 Frauenfelder et al.\textsuperscript{56} 2014 |
| CT: computed tomography; HRCT: high-resolution computed tomography.\textsuperscript{a} These estimates of effective dose are provided to show a relative comparison between different CT exams and to put them in some context as to their relative level of radiation exposure. It should be noted that both the American Association of Physicists in Medicine and the Health Physics Society have position statements which state that “at the present time, epidemiologic evidence supporting increased cancer incidence or mortality from radiation doses below 100 mSv is inconclusive”\textsuperscript{60} and “substantial and convincing scientific data show evidence of health effects following high-dose exposures (many multiples of natural background). However, below levels of about 100 mSv above background from all sources combined, the observed radiation effects in people are not statistically different from zero.”\textsuperscript{67} The actual effective dose that a patient experiences will vary from center to center.\textsuperscript{b}
physicists) of 50 mSv per year. The International Commission on Radiological Protection has also recommended an annual average of not more than 20 mSv per year over a 5-year period for occupational exposure.65

**Computer-based quantification of fibrosis in patients with SSc-ILD**

Computer-aided diagnosis algorithms for classifying HRCT patterns in diffuse lung disease for SSc-ILD were first reported in 2010. This algorithm was developed using a machine-learned texture feature classification to detect and quantitate the amount of ground glass (QGG), lung fibrosis (QLF), and honeycomb cysts in patients with SSc-ILD. QGG and QLF have been used in several settings to determine the measurement variation and cut points for meaningful change.7 The extent of QLF is a predictor of decline in FVC over a 1-year period and is independent of the staging system used to classify extent of disease.42 Other algorithms, including the automated lung parenchymal characterization by computer-aided lung informatics for pathology evaluation and rating (CALIPER), were also developed using a computer-visions-based technique that includes volumetric local histogram and morphologic analysis to provide quantitative assessment of pulmonary parenchymal disease on HRCT data. These algorithms can objectively quantify specific patterns of ILD changes during treatment in patients with SSc-ILD.45,47 Results have been found to be equivalent to or better than those of a radiologist,9,70,71 although these algorithms are patented and not widely available.

More recently, artificial intelligence and deep learning have been applied to the classification of fibrotic lung disease on HRCT, using criteria specified by two international diagnostic guideline statements. The algorithm developed therein was able to differentiate between UIP, possible UIP, and patterns inconsistent with UIP with 73.3% accuracy, and the authors note that this could be applicable in centers lacking in radiologic expertise.72

**Emerging imaging techniques**

**Lung ultrasound**

Lung ultrasound is sensitive for the detection of lung disease but not as specific as HRCT.73–75 Lung ultrasound abnormalities correlate with increases in the score and digital vascular damage when assessing progression of ILD.76 B-lines on lung ultrasound show mild-to-moderate correlation with fibrosis on HRCT77 and detection of multiple B-lines, pleural irregularity, and pleural line thickening on lung ultrasound is highly predictive of the presence of significant SSc-ILD on HRCT.78,79 However, there is not yet a consensus on whether lung ultrasound can be used routinely to screen for ILD in SSc.

**Other imaging techniques**

Magnetic resonance imaging (MRI) techniques show promise in the detection of pulmonary fibrosis.80,81 While HRCT has superior image quality, MRI may be useful to detect inflammatory changes and is free of any radiation exposure. As a molecular imaging modality, positron emission tomography (PET)-CT is being studied as a potential monitoring tool. 18 F-fluorodeoxyglucose (FDG) is a commonly used PET radiotracer in oncology. In lung fibrosis, FDG uptake has been observed in macrophages, neutrophils, and eosinophils and may detect cellular inflammation through the glycolysis of immune cells, as an indirect means to monitor fibrosis.82 Single-photon emission CT (SPECT) has potential utility in the early detection of ILD, by using radiolabeled, target-specific probes to visualize inflammatory stages of ILD. Preclinical studies in animal models and resections from human lungs have shown that SPECT could potentially identify ILD before significant tissue remodeling has occurred.83,84 These promising tools need further evaluation in the screening and management of SSc-ILD.

**Conclusion**

HRCT is currently the gold standard for early detection and accurate diagnosis of ILD in patients with SSc and should be performed in all patients at the time of initial SSc diagnosis. Patients most at risk of developing ILD are those with a recent diagnosis of SSc, diffuse cutaneous SSc, smoking history or male gender, and these should be considered when determining whether a patient would benefit from regular screening. HRCT can also be used for prognosis and to monitor for disease progression in addition to serial lung function tests and other measures. Currently, follow-up HRCT is guided by symptoms and suspicion of progression, and more research is needed on the optimal frequency in patients at different levels of ILD risk.

As HRCT scan techniques are constantly evolving, low-radiation protocols that are suitable for the regular screening and monitoring of patients are now available. The introduction of other technologies, such as lung ultrasound or MRI, with or without HRCT, is a potential future direction that may further assist in the evaluation of patients with SSc-ILD.

**Acknowledgements**

Medical writing, editorial support, and formatting assistance for this manuscript was provided by Rebecca Sutch, PhD, of AMICULUM and Helen Keyworth, PhD, of Nucleus Global under the authors’ conceptual direction and based on feedback from the authors, and was contracted and funded by Boehringer Ingelheim International GmbH (B.I.). B.I was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.
Author contributions
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript. All authors reviewed and revised the manuscript critically for important intellectual content; and approved the final version of the manuscript. The authors take full responsibility for the scope, direction, content of, and editorial decisions relating to the manuscript, were involved at all stages of development, and have approved the submitted manuscript.

Declaration of conflicting interests
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.K. reports consultancies with Acceleron, Actelion, Bayer, BMS, Boehringer Ingelheim, Corbus, Galapagos, Genentech/Roche, GSK, Mitsubishi Tanabe, Sanofi-Aventis/Genzyme; and stock ownership or options with Eicos Sciences, Inc. O.D. has/had a consultancy relationship with and/or has received research funding from: Abbvie, Acceleron Pharma, Amgen, AnaMar, Bayer, Boehringer Ingelheim, Catenion, Drug Development International Ltd, CSL Behring, ChemomAb, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, Ihalfarmaco, IQVIA, Lilly, Medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Serodapharm, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, O.D. has a patent issued for mir-29 for the treatment of systemic sclerosis (US247389, EP2331143). V.C. reports personal fees and non-financial support from Actelion; grants, personal fees and non-financial support from Boehringer Ingelheim and Roche; and personal fees from Bayer, MSD, Novartis, Sanofi, Promedior, Celgene, Galapagos and Galecto outside the submitted work. K.K.B. reports personal fees from Bayer, MSD, Novartis, Sanofi, Promedior, Celgene, Galapagos and Galecto outside the submitted work. K.K.B. reports personal fees from Bayer, MSD, Novartis, Sanofi, Promedior, Celgene, Galapagos, Galecto, Genoa, Lifemax, MedImmune, OSI (Open Source Imaging Consortium), Pliant, ProMetic, Third Pole, Theravance, Three Lakes Partners, Veracyte; personal fees and non-financial support from Actelion and Boehringer Ingelheim; grants from NIH; consultancies with Biogen and Blade; and grants, personal fees and non-financial support from Roche outside the submitted work. L.C. has served on scientific advisory boards for Boehringer Ingelheim and Mitsubishi Tanabe; serves on a steering committee for Eicos and a data monitoring safety board for Reata; and receives grant funding from Boehringer Ingelheim and United Therapeutics. J.G.G. is the founder of MedQIA, LLC. E.L.M. has a consultancy relationship and/or has received research funding from Boehringer Ingelheim and Gilead. E.K. has no potential conflicts of interest to disclose. S.L.F.W. reports personal fees from Boehringer Ingelheim; grants from National Institute for Health and Research, outside the submitted work. M.M.-G. is a member of a scientific advisory board for Hura Imaging, Inc.; received research funding from Siemens Healthineers and UCLA Radiological Sciences and has a Master Research Agreement with Siemens Healthineers. T.M.M. received research funding and/or consulting fees or other remuneration from AstraZeneca, Bayer, Boehringer Ingelheim, Biogen, Cipla, GSK, Prometic, Roche, Samumed and UCB; and has stock options or bond holdings in the for-profit corporation Apellis.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing support was contracted and funded by Boehringer Ingelheim International GmbH.

ORCID iD
Dinesh Khanna https://orcid.org/0000-0003-1412-4453

References

1. Khanna D, Tashkin DP, Denton CP, et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201: 650–660.
2. Denton CP, Hughes M, Gak N, et al. BSR and BHRP guideline for the treatment of systemic sclerosis. Rheumatology 2016; 55(10): 1906–1910.
3. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76(8): 1327–1339.
4. Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology 2020; 2: e71–e83.
5. Hansell DM, Goldin JG, King TE Jr, et al. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med 2015; 3(6): 483–496.
6. Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15: 10.
7. Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014; 273(2): 570–579.
8. Kim GHJ, Tashkin DP, Lo P, et al. Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol 2019; 72: 316–325.
9. Wu X, Kim GH, Salisbury ML, et al. Computed tomographic biomarkers in idiopathic pulmonary fibrosis. The future of quantitative analysis. Am J Respir Crit Care Med 2019; 199: 12–21.
10. Bernstein EJ, Khanna D and Lederer DJ. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol 2018; 70(6): 971–972.
11. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747–1755.
12. Sanchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the
Spanish Scleroderma Study Group. *Rheumatol Int* 2018; 38(3): 363–374.

13. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. *Ann Rheum Dis* 2017; 76(11): 1897–1905.

14. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. *Rheumatology* 2013; 52(1): 155–160.

15. Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive lung fibrosis in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. *Arthritis Rheumatol* 2018; 70: A799.

16. Hoffman-Vold A-M, Allanore Y, Alves M, et al. Prediction and frequency of progressive lung fibrosis in patients with systemic sclerosis-associated interstitial lung disease in the world’s largest database of patients with systemic sclerosis (EUSTAR). *Am J Respir Crit Care Med* 2019; 199: A5615 (Poster presented at the American Thoracic Society (abstract 12910), Dallas, TX), https://doi.org/10.1164/ajrccm-conference.2019.199.1.MeetingAbstracts.A5615

17. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. *Arthritis Rheumatol* 2014; 66(6): 1625–1635.

18. Liaskos C, Marou E, Simopoulos T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. *Autoimmunity* 2017; 50(7): 414–421.

19. Steen V, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. *Arthritis Rheum* 2012; 64(9): 2986–2994.

20. Zhang XJ, Bonner A, Hudson M, et al. Association of gastrosophageal factors and worsening of forced vital capacity in systemic sclerosis. *J Rheumatol* 2013; 40(6): 850–858.

21. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. *Chest* 2014; 146(2): 422–436.

22. Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. *Clin Exp Rheumatol* 2015; 33(4, Suppl. 91): S111–S116.

23. Hoffmann-Vold A-M, Aalokken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. *Arthritis Rheumatol* 2015; 67(8): 2205–2212.

24. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008; 177: 1248–1254.

25. Wangkaew S, Euathrongchit J, Wattanawittawas P, et al. Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients. *Quant Imaging Med Surg* 2016; 6(4): 381–390.

26. Wu W, Jordan S, Becker MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. *Ann Rheum Dis* 2018; 77(9): 1326–1332.

27. Guler SA, Winstone TA, Murphy D, et al. Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. *Ann Am Thorac Soc* 2018; 15(12): 1427–1433.

28. Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. *Am J Respir Crit Care Med* 2019; 200: 1258–1266.

29. Hoffmann-Vold AM, Distler O, Murray B, et al. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. *RMD Open* 2019; 5(1): e000826.

30. Ariani A, Silva M, Bravi E, et al. Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis. *RMD Open* 2019; 5(1): e000820.

31. Champtiaux N, Cottin V, Chassagnon G, et al. Combined pulmonary fibrosis and emphysema in systemic sclerosis: a syndrome associated with heavy morbidity and mortality. *Semin Arthritis Rheum* 2019; 49(1): 98–104.

32. Chung J, Walker CM and Hobbs S. Imaging features of systemic sclerosis-associated interstitial lung disease. *J Vis Exp*. Epub ahead of print 16 June 2020. DOI: 10.3791/60300.

33. Suliman YA, Dobrota R, Huscher D, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. *Arthritis Rheumatol* 2015; 67(12): 3256–3261.

34. Showalter K, Hoffmann A, Rouleau G, et al. Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis. *J Rheumatol* 2018; 45(11): 1572–1576.

35. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. *Am J Respir Crit Care Med* 2018; 198: 767–776.

36. Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. *Eur Respir J* 2019; 53(1): 1800869.

37. Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. *J Rheumatol* 2002; 29(11): 2371–2378.

38. Jacob J, Bartholmai BJ, van Moorsel CHM, et al. Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. *Eur Respir J* 2019; 54(3): 1802341.

39. Roth MD, Tseng C-H, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. *Arthritis Rheumatol* 2019; 70: A1622.

40. Roybdell M, Lamlum J, Kallen B, et al. High-resolution computed tomographic findings in systemic sclerosis-associated interstitial lung disease: comparison between diffuse and limited systemic sclerosis. *J Clin Rheumatol* 2012; 18(5): 229–233.

41. Le Gouellec N, Duhamel A, Perez T, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. *PLoS ONE* 2017; 12(8): e0181692.

42. Khanna D, Nagaraja V, Tseng CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung
disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. *Arthritis Res Ther* 2015; 17: 372.

43. Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. *J Rheumatol* 2006; 33(9): 1789–1801.

44. Takei R, Arita M, Kumagai S, et al. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. *Respirology* 2018; 23(4): 385–391.

45. Goldin JG, Kim GHJ, Tseng CH, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. *Ann Am Thorac Soc* 2018; 15(11): 1286–1295.

46. Kim HJ, Tashkin DP, Gjertson DW, et al. Effect of iterative reconstruction on the detection of systemic sclerosis-related interstitial lung disease. *Respiration* 2017; 93(1): 15–22.

47. Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. *Eur Radiol* 2011; 21(12): 2455–2465.

48. Zerhouni EA, Naidich DP, Stitik FP, et al. Computed tomography of the pulmonary parenchyma. Part 2: interstitial disease. *J Thorac Imaging* 1985; 1: 54–64.

49. Thomson CC, Duggal A, Bice T, et al. 2018 clinical practice guideline summary for clinicians: diagnosis of idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2019; 16(3): 285–290.

50. Katsura M, Sato J, Akahane M, et al. Effects of pure and hybrid iterative reconstruction algorithms on high-resolution computed tomography in the evaluation of interstitial lung disease. *Eur J Radiol* 2017; 93: 243–251.

51. Beigelman-Aubry C, Hill C, Guibal A, et al. Multi-detector row CT and postprocessing techniques in the assessment of diffuse lung disease. *Radiographics* 2005; 25(6): 1639–1652.

52. National Research Council. *Health physics in perspective: position statement of the Health Physics Society*. Herndon, VA: Health Physics Society, 2016.

53. Wakeford R. NCRP report no. 160: ionizing radiation exposure of the population of the United States. Report no. 160. Bethesda, MD: National Council on Radiation Protection and Measurements.

54. Bagshaw M. Cosmic radiation in commercial aviation. *Travel Med Infect Dis* 2008; 6(3): 125–127.

55. United States Nuclear Regulatory Commission. NRC Regulations: Title 10, Code of Federal Regulations Part 20—Standards for Protection against Radiation, https://www.nrc.gov/reading-rm/doc-collections/cfr/part020/full-text.html (2019, accessed 13 February 2020).

56. American Association of Physicists in Medicine. Lung cancer screening CT (2019 update), https://www.aapm.org/pubs/CTProtocols/documents/LungCancerScreeningCT.pdf (2019, accessed 13 February 2020).

57. Mettler FA Jr, Huda W, Yoshizumi TT, et al. Effective doses in radiology and diagnostic nuclear medicine: a catalog. *Radiology* 2008; 248(1): 254–263.

58. American Association of Physicists in Medicine. Lung cancer screening CT (2019 update), https://www.aapm.org/pubs/CTProtocols/documents/LungCancerScreeningCT.pdf (2019, accessed 13 February 2020).

59. Khanna et al. Integrated use of lung ultrasound and chest X-ray in the detection of interstitial lung disease. *Respiration* 2017; 93(1): 15–22.
74. Barskova T, Gargani L, Guiducci S, et al. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. *Ann Rheum Dis* 2013; 72(3): 390–395.

75. Mohammadi A, Oshnoei S and Ghasemi-rad M. Comparison of a new, modified lung ultrasonography technique with high-resolution CT in the diagnosis of the alveolo-interstitial syndrome of systemic scleroderma. *Med Ultrason* 2014; 16(1): 27–31.

76. Gigante A, Rossi Fanelli F, Lucci S, et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. *Intern Emerg Med* 2016; 11: 213–217.

77. Gargani L, Doveri M, D’Errico L, et al. Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. *Rheumatology* 2009; 48(11): 1382–1387.

78. Tardella M, Di Carlo M, Carotti M, et al. Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: cut-off point definition for the presence of significant pulmonary fibrosis. *Medicine* 2018; 97(18): e0566.

79. Pinal-Fernandez I, Pallisa-Nunez E, Selva-O’Callaghan A, et al. Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisyntetase syndrome. *Clin Exp Rheumatol* 2015; 33(4, Suppl. 91): S136–S141.

80. Lavelle LP, Brady D, McEvoy S, et al. Pulmonary fibrosis: tissue characterization using late-enhanced MRI compared with unenhanced anatomic high-resolution CT. *Diagn Interv Radiol* 2017; 23(2): 106–111.

81. Mirsadraee S, Tse M, Kershaw L, et al. T1 characteristics of interstitial pulmonary fibrosis on 3T MRI—a predictor of early interstitial change? *Quant Imaging Med Surg* 2016; 6(1): 42–49.

82. Baues M, Dasgupta A, Ehling J, et al. Fibrosis imaging: current concepts and future directions. *Adv Drug Deliv Rev* 2017; 121: 9–26.

83. Schniering J, Benešová M, Brunner M, et al. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. *Ann Rheum Dis* 2019; 78: 218–227.

84. Schniering J, Guo L, Brunner M, et al. Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis. *Arthritis Res Ther* 2018; 20: 183.